{"paper_id":"870d70f7-4932-4852-8167-303e9b4c0557","body_text":"Abstract\nSubtle alterations in coagulation and fibrinolysis have been recently reported in patients with endometriosis supporting a potential hypercoagulable status associated with the disease. This cross-sectional study aimed at evaluating some variables of coagulation status and inflammatory markers in women with endometriosis. A total of 314 women who underwent surgery were considered. The case group (n = 169) included patients with a surgical diagnosis of endometriosis, at any stage of disease. The control group (n = 145) included women with a surgical diagnosis of benign gynecologic pathology. No difference was found for thrombin time, International Normalized Ratio (INR), platelet count, neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio (PLR) between women with endometriosis and controls. Conversely, patients with endometriosis had significantly shortened activated partial thromboplastin time (APTT) when compared to controls (1.08 ± 0.06 and 1.12 ± 0.19, respectively; P <.01). In the subgroup analysis, women with ovarian endometriosis had significantly shortened APTT values in comparison to women without this form and women with stage I to II endometriosis had significantly shorter APTT values and higher PLR than those with stage III to IV disease. In multivariate logistic regression analysis, after controlling for potential confounders, a shortened APTT remained associated with the disease. Activated partial thromboplastin time is shorter in women with endometriosis but still in the normal range. The evidence is insufficient to foresee a possible use of APTT as a diagnostic marker and to claim a crucial role of a systemic hypercoagulable state in the origin of the disease. A role of the local coagulation system in the pathogenesis of the disease cannot be excluded.\nSimilar content being viewed by others\nReferences\nKvaskoff M, Mu F, Terry KL, et al. Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update. 2015;21(4):500–516.\nZuin M, Rigatelli G, Stellin G, Faggian G, Roncon L. Should women with endometriosis be screened for coronary artery disease? Eur J Intern Med. 2016;35:e19–e20.\nLobo RA, Surgical menopause and cardiovascular risks. Menopause. 2007;14(3):562–566.\nAlhurani RE, Chahal CA, Ahmed AT, Mohamed EA, Miller VM. Sex hormone therapy and progression of cardiovascular disease in menopausal women. Clin Sci (Lond). 2016;130(13):1065–1074.\nWu Q, Ding D, Liu X, Guo SW. Evidence for a hypercoagulable state in women with ovarian endometriomas. Reprod Sci. 2015;22(9):1107–1114.\nTokmak A, Yildirim G, Oztas, E, et al. Use of neutrophil-to-lymphocyte ratio combined with CA-125 to distinguish endometriomas from other benign ovarian cysts. Reprod Sci. 2016;23(6):795–802.\nYavuzcan A, Caglar M, Ustiin Y, et al. Evaluation of mean platelet volume, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma. J Turk Ger Gynecol Assoc. 2013;14(4):210–215.\nYang H, Zhu L, Wang S, Lang J, Xu T. Noninvasive diagnosis of moderate to severe endometriosis: the platelet-lymphocyte ratio cannot be a neoadjuvant biomarker for serum cancer antigen 125. J Minim Invasive Gynecol. 2015;22(3):373–377.\nLin M, Weng H, Wang X, Zhou B, Yu P, Wang Y. The role of tissue factor and protease-activated receptor 2 in endometriosis. Am J Reprod Immunol. 2012;68(3):251–217.\nOsuga Y, Hirota Y, Yoshino O, Hirata T, Koga K, Taketani Y. Proteinase-activated receptors in the endometrium and endometriosis. Front Biosci (Schol Ed). 2012;4:1201–1212.\nCho S, Cho H, Nam A, et al. Neutrophil-to-lymphocyte ratio as an adjunct to CA-125 for the diagnosis of endometriosis. Fertil Steril. 2008;90(6):2073–2079.\nKim SK, Park JY, Jee BC, Suh CS, Kim SH. Association of the neutrophil-to-lymphocyte ratio and CA 125 with the endometriosis score. Clin Exp Reprod Med. 2014;41(4):151–157.\nAnderson JA, Weitz JI. Hypercoagulable states. Crit Care Clin. 2011;27(4):933–952.\nSanchez AM, Vigano P, Somigliana E, Panina-Bordignon P, Vercellini P, Candiani M. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma-mediated damage to the ovary. Hum Reprod Update. 2014;20(2):217–230.\nAmerican Society for Reproductive Medicine 1997. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67(5):817–821.\nvan Rooijen M, Silveira A, Thomassen S, et al. APC resistance during the normal menstrual cycle. Thromb Haemost. 2007;98(6):1246–1251.\nTchaikovski SN, Thomassen MC, Costa SD, Bremme K, Rosing J. Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives. Thromb Res. 2014;134(5):1032–1037.\nSenthil M, Chaudhary P, Smith DD, et al. A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients. Thromb Res. 2014;134(1):165–168.\nGentilini D, Perino A, Vigano P, et al. Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases. Hum Reprod. 2011;26(11):3109–3117.\nLeone Roberti Maggiore U, Ferrero S, Mangili G, et al. A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes. Hum Reprod Update. 2016;22(1):70–103.\nSanchez AM, Somigliana E, Vercellini P, Pagliardini L, Candiani M, Vigano P. Endometriosis as a detrimental condition for granulosa cell steroidogenesis and development: from molecular alterations to clinical impact. J Steroid Biochem Mol Biol. 2016;155(ptA):35–46.\nVercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275.\nVigano P, Somigliana E, Panina P, Rabellotti E, Vercellini P, Candiani M. Principles of phenomics in endometriosis. Hum Reprod Update. 2012;18(3):248–259.\nLevi M, van der Poll T. Inflammation and coagulation. Crit Care Clin. 2010;38(suppl):S27–S34.\nLevi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost. 2006;32(1):33–39.\nSanchez AM, Vigano P, Somigliana E, Cioffi R, Panina-Bordignon P, Candiani M. The endometriotic tissue lining the internal surface of endometrioma: hormonal, genetic, epigenetic status, and gene expression profile. Reprod Sci. 2015;22(4):391–401.\nLevi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33.\nFujiwara H, Kosaka K, Hamanishi S, et al. Acute elevation of plasma D-dimer levels associated with rupture of an ovarian endometriotic cyst: case report. Hum Reprod. 2003;18(2):338–341.\nKline JA, Runyon MS, Webb WB, Jones AE, Mitchell AM. Prospective study of the diagnostic accuracy of the simplify D-dimer assay for pulmonary embolism in emergency department patients. Chest. 2006;129(6):1417–1423.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nViganò, P., Ottolina, J., Sarais, V. et al. Coagulation Status in Women With Endometriosis. Reprod. Sci. 25, 559–565 (2018). https://doi.org/10.1177/1933719117718273\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1177/1933719117718273","source_license":"CC0","license_restricted":false}